Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Biotechnology_Personalized, Precision, Preemptive Medicines
IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Organization & Developments: IDEAYA Biosciences

Parents

*Ideaya Biosciences, Inc. (NASDAQ: IDYA) is a synthetic lethality focused precision medicine oncology company committed to the discovery and development of targeted therapeutics
2022: Ideaya Biosciences: Prospects Rebound With Updated Uveal Melanoma Data_seekingalpha.com
2023: Ideaya Biosciences: Advancing Pipeline, Further Evidence Needed For Immediate Entry_ seekingalpha.com
2024: IDEAYA Announces Positive Interim Phase 1 Expansion Data of IDE397 in MTAP-Deletion Urothelial and Lung Cancer as Late-Breaker Oral Presentation at EORTC-NCI-AACR 2024
2024: Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success_ seekingalpha.com
2024: Ideaya Biosciences: A Strong Bet In Targeted Oncology
2024: Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash
2024: IDEAYA’s rare cancer drug shows promise as company lays out Phase III plans
2025: IDEAYA Biosciences Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma
2025: Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849
2026: Ideaya Biosciences: Stock Buoyant On Good mUM Data - But Approval Not A Formality (IDYA)